Loading company…
Orion Biotechnology develops therapeutics targeting metabolic GPCRs and related disorders.
Founded in 2017 and based in Ottawa, Orion Biotechnology researches therapeutics targeting metabolic G Protein-Coupled Receptors, including for obesity and metabolic disorders. Its candidates include OB-002 and OB-003, targeting the GPR75 receptor. In June 2021, it raised USD 11.5 mn in Series A funding led by Keiretsu Forum.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in